{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:20:43Z","timestamp":1793920843597,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["17H04282"],"award-info":[{"award-number":["17H04282"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["17K19698"],"award-info":[{"award-number":["17K19698"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16K15615"],"award-info":[{"award-number":["16K15615"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["15H05791"],"award-info":[{"award-number":["15H05791"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16K15615"],"award-info":[{"award-number":["16K15615"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["15H05791"],"award-info":[{"award-number":["15H05791"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["17H04282"],"award-info":[{"award-number":["17H04282"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["17K19698"],"award-info":[{"award-number":["17K19698"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer stem cells (CSCs) are involved in metastatic colorectal cancer recurrence, but no effective therapy targeting these cells is currently available. Because trifluridine (FTD)\/tipiracil therapy is used for refractory colorectal cancer, we sought to determine whether FTD is effective against CSC-like cells. CD44<jats:sup>+<\/jats:sup>CD133<jats:sup>+<\/jats:sup>high-expressing and other populations of human DLD-1 colon cancer cells were separately isolated through fluorescence-activated cell sorting. The sphere-forming activity of each population and the anti-sphere-forming effects of FTD and fluorouracil (5-FU) on CD44<jats:sup>+<\/jats:sup>CD133<jats:sup>+<\/jats:sup>cells were then measured. CD44<jats:sup>+<\/jats:sup>CD133<jats:sup>+<\/jats:sup>DLD-1 cells formed substantially more spheres than other cells. Moreover, treating CD44<jats:sup>+<\/jats:sup>CD133<jats:sup>+<\/jats:sup>DLD-1 cells with subtoxic concentrations of FTD (1\u2009\u00b5M) inhibited sphere formation, and this was superior to the effect of subtoxic concentrations (1\u2009\u00b5M) of 5-FU. The associated inhibition rates for FTD and 5-FU were 58.2% and 26.1%, respectively. Further, CD44<jats:sup>+<\/jats:sup>CD133<jats:sup>+<\/jats:sup>DLD-1 cells expressed higher levels of thymidine kinase 1, which is responsible for FTD phosphorylation, than DLD-1 cells, and FTD was incorporated into the DNA of CD44<jats:sup>+<\/jats:sup>CD133<jats:sup>+<\/jats:sup>DLD-1 cells. Thus, our data show that FTD treatment is effective against CSC-like cells and might be applied as CSC-targeting chemotherapy for tumor subtypes with high CD44 and CD133 expression.<\/jats:p>","DOI":"10.1038\/s41598-019-50968-6","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T10:07:34Z","timestamp":1571220454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["CD44\/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure"],"prefix":"10.1038","volume":"9","author":[{"given":"Kenta","family":"Tsunekuni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6960-2315","authenticated-orcid":false,"given":"Masamitsu","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotsugu","family":"Haraguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Koseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobunai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8552-9170","authenticated-orcid":false,"given":"Teiji","family":"Takechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"50968_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature05372","volume":"445","author":"CA O\u2019Brien","year":"2007","unstructured":"O\u2019Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106\u2013110 (2007).","journal-title":"Nature"},{"key":"50968_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature05384","volume":"445","author":"L Ricci-Vitiani","year":"2007","unstructured":"Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111\u2013115 (2007).","journal-title":"Nature"},{"key":"50968_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.stem.2007.08.001","volume":"1","author":"M Todaro","year":"2007","unstructured":"Todaro, M. et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1, 389\u2013402 (2007).","journal-title":"Cell Stem Cell"},{"key":"50968_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.stem.2014.11.012","volume":"15","author":"A Zeuner","year":"2014","unstructured":"Zeuner, A., Todaro, M., Stassi, G. & De Maria, R. Colorectal cancer stem cells: From the crypt to the clinic. Cell Stem Cell 15, 692\u2013705 (2014).","journal-title":"Cell Stem Cell"},{"key":"50968_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23, 1124\u20131134 (2017).","journal-title":"Nat. Med."},{"key":"50968_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/annotation\/dd945f7c-c50b-461d-ab38-15e8b0966458","volume":"8","author":"S Chen","year":"2013","unstructured":"Chen, S. et al. CD133 Expression and the prognosis of colorectal cancer: A systematic review and meta-analysis. PLoS One 8, 1\u20139 (2013).","journal-title":"PLoS One"},{"key":"50968_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","volume":"14","author":"A Kreso","year":"2014","unstructured":"Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell Stem Cell 14, 275\u2013291 (2014).","journal-title":"Cell Stem Cell"},{"key":"50968_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2011.01.038","volume":"19","author":"T Ishimoto","year":"2011","unstructured":"Ishimoto, T. et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc- and thereby promotes tumor growth. Cancer Cell 19, 387\u2013400 (2011).","journal-title":"Cancer Cell"},{"key":"50968_CR9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1080\/07357900902744502","volume":"27","author":"D Horst","year":"2009","unstructured":"Horst, D., Kriegl, L., Engel, J., Kirchner, T. & Jung, A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 27, 844\u2013850 (2009).","journal-title":"Cancer Invest."},{"key":"50968_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1440-1827.2011.02760.x","volume":"62","author":"Y Wakamatsu","year":"2012","unstructured":"Wakamatsu, Y. et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol. Int. 62, 112\u2013119 (2012).","journal-title":"Pathol. Int."},{"key":"50968_CR11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","volume":"13","author":"T Yoshino","year":"2012","unstructured":"Yoshino, T. et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 13, 993\u20131001 (2012).","journal-title":"Lancet Oncol."},{"key":"50968_CR12","first-page":"1","volume":"102","author":"C Eng","year":"2019","unstructured":"Eng, C. et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 102, 1\u201313 (2019).","journal-title":"Lancet Oncol."},{"key":"50968_CR13","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909\u20131919 (2015).","journal-title":"N. Engl. J. Med."},{"key":"50968_CR14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0006-2952(00)00253-7","volume":"59","author":"M Fukushima","year":"2000","unstructured":"Fukushima, M. et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2\u2032-deoxyribonucleosides. Biochem. Pharmacol. 59, 1227\u20131236 (2000).","journal-title":"Biochem. Pharmacol."},{"key":"50968_CR15","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1158\/0008-5472.CAN-08-2023","volume":"69","author":"NA Dallas","year":"2009","unstructured":"Dallas, N. A. et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 69, 1951\u20131957 (2009).","journal-title":"Cancer Res."},{"key":"50968_CR16","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.3892\/ijo.2015.2974","volume":"46","author":"K Sakamoto","year":"2015","unstructured":"Sakamoto, K. et al. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2\u2032-deoxy-5-fluorouridine into DNA. Int. J. Oncol. 46, 2327\u20132334 (2015).","journal-title":"Int. J. Oncol."},{"key":"50968_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/1758834015603313","volume":"7","author":"GJ Peters","year":"2015","unstructured":"Peters, G. J. Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies. Ther. Adv. Med. Oncol. 7, 340\u2013356 (2015).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"50968_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"H Kitao","year":"2016","unstructured":"Kitao, H. et al. The antibodies against 5-bromo-2\u2032-deoxyuridine specifically recognize trifluridine incorporated into DNA. Sci. Rep. 6, 1\u201312 (2016).","journal-title":"Sci. Rep."},{"key":"50968_CR19","doi-asserted-by":"crossref","first-page":"7657","DOI":"10.18632\/oncotarget.7084","volume":"7","author":"J-Y Zhou","year":"2016","unstructured":"Zhou, J.-Y. et al. Role of CD44high\/CD133high HCT-116 cells in the tumorigenesis of colon cancer. Oncotarget 7, 7657\u20137666 (2016).","journal-title":"Oncotarget"},{"key":"50968_CR20","first-page":"810","volume":"29","author":"YH Deng","year":"2010","unstructured":"Deng, Y. H. et al. 5 Fluorouracil upregulates the activity of Wnt signaling pathway in CD133positive colon cancer stemlike cells. Chin. J. Cancer 29, 810\u2013815 (2010).","journal-title":"J. Cancer"},{"key":"50968_CR21","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/sj.onc.1210811","volume":"27","author":"S Ma","year":"2008","unstructured":"Ma, S., Lee, T. K., Zheng, B., Chan, K. W. & Guan, X. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt\/PKB survival pathway. Oncogene 27, 1749\u20131758, https:\/\/doi.org\/10.1038\/sj.onc.1210811 (2008).","journal-title":"Oncogene"},{"key":"50968_CR22","doi-asserted-by":"crossref","first-page":"77734","DOI":"10.18632\/oncotarget.20774","volume":"8","author":"H-W Yeh","year":"2017","unstructured":"Yeh, H.-W. et al. Pyrimidine metabolic rate limiting enzymes in poorly-differentiated hepatocellular carcinoma are signature genes of cancer stemness and associated with poor prognosis. Oncotarget 8, 77734\u201377751 (2017).","journal-title":"Oncotarget"},{"key":"50968_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-018-0633-9","volume":"18","author":"EG Weagel","year":"2018","unstructured":"Weagel, E. G. et al. Membrane expression of thymidine kinase 1 and potential clinical relevance in lung, breast, and colorectal malignancies. Cancer Cell Int. 18, 135 (2018).","journal-title":"Cancer Cell Int."},{"key":"50968_CR24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1016-8478(23)12862-7","volume":"21","author":"CG Kim","year":"2006","unstructured":"Kim, C. G. et al. Profiling of differentially expressed genes in human stem cells by cDNA microarray. Mol. Cells 21, 343\u2013355 (2006).","journal-title":"Mol. Cells"},{"key":"50968_CR25","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara, K. et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreatedmetastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled,phase 3 trial. Lancet Oncol 19, 1437\u20131448 (2018).","journal-title":"Lancet Oncol"},{"key":"50968_CR26","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/cncr.30538","volume":"123","author":"T Bekaii-Saab","year":"2017","unstructured":"Bekaii-Saab, T. & El-Rayes, B. Identifying and targeting cancer stem cells in the treatment of gastric cancer. Cancer 123, 1303\u20131312 (2017).","journal-title":"Cancer"},{"issue":"suppl_5","key":"50968_CR27","first-page":"O","volume":"29","author":"E Van Cutsem","year":"2018","unstructured":"Van Cutsem, E. et al. Abstracts. Annals of Oncol. 29(suppl_5), O\u2013022 (2018).","journal-title":"Annals of Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50968-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50968-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50968-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T02:43:45Z","timestamp":1721875425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50968-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["50968"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-50968-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"19 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded by Taiho Pharmaceutical Co., Ltd (Tokyo, Japan), Evidence Based Medical Research Center INC. (Osaka, Japan), Unitech Co., Ltd. (Chiba, Japan), IDEA Consultants, Inc. (Tokyo, Japan), and Kinshu-kai Medical Corporation (Osaka, Japan). K.T., K.M., T.K., and T.T., are employees of Taiho Pharmaceutical Co. Ltd (Tokyo, Japan).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14861"}}